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Abstract The mechanisms of action of Ewing’s sarcoma
(EWS) associated EWS-ETS oncoproteins have largely re-
mained unresolved. Here, we analyzed how two EWS-ETS pro-
teins, EWS-ER81 and EWS-Fli-1, in vitro activate the matrix
metalloproteinase (MMP)-1 promoter that is upregulated in a
subset of EWSs. EWS-ER81 and EWS-Fli-1 interact with and
thereby activate the MMP-1 promoter, which is potentiated by
the cofactor p300 and the proto-oncoprotein c-Jun. Further,
EWS-ER81 binds to c-Jun in vitro and in vivo. The interaction
between c-Jun, p300 and EWS-ER81 or EWS-Fli-1 may also be
relevant to the regulation of other yet-to-be-identi¢ed genes that
are responsible for EWS formation.
. 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Ewing’s sarcoma (EWS) is a highly aggressive malignancy
a¡ecting predominantly children. Several chromosomal trans-
locations speci¢c for EWS have been described and de¢ne it
as a distinct clinicopathologic entity [1]. As a result of these
chromosomal translocations, EWS-ETS fusion proteins are
generated in which the N-terminal domain (NTD) is derived
from the EWS gene product whereas the C-terminal domain
(CTD) consists of a DNA binding domain derived from one
out of ¢ve ETS transcription factors [1]. EWS-ETS fusion
proteins are aberrant transcription factors and oncoproteins
that promote anchorage independent cell growth and tumor
formation [2,3]. Furthermore, continued expression of EWS-
ETS fusion genes is necessary for maintaining EWS histology
and growth [4].
Matrix metalloproteinase (MMP)-1, also known as intersti-
tial collagenase, belongs to a class of proteases that regulate
the function of many bioactive molecules by proteolytic
processing [5]. MMPs also mediate extracellular matrix and
basement-membrane degradation during the early stages of
tumorigenesis, contributing to the formation of a micro-
environment that promotes tumor growth. In later stages of
cancer development, MMPs promote metastasis as well as
other aspects of tumor growth [6].
Since MMP-1 has been shown to be regulated by many
ETS proteins [7] and EWS-ETS fusion proteins are endowed
with an ETS DNA binding domain, we hypothesized that
MMP-1 is a target gene for EWS-ETS proteins. Indeed, the
EWS-ER81 and EWS-Fli-1 fusion proteins can interact with
the MMP-1 promoter and collaborate with c-Jun and the
cofactor p300 to activate MMP-1 gene transcription in vitro.
2. Materials and methods
2.1. Reporter gene assays
Equal numbers of cells were transiently transfected by the calcium
phosphate coprecipitation method [8]. 36 h after transfection, cells
were lysed in 25 mM Tris^HCl (pH 7.8), 2 mM EDTA, 10% glycerol,
1% Triton X-100, 2 mM dithiothreitol (DTT) for 5 min. Plates were
then scraped and the extract was collected and centrifuged at
20 800Ug for 1 min. The cleared supernatant was then assayed for
luciferase activity [8]. Each of these experiments was repeated at least
three times, and the mean values and standard deviations are indi-
cated.
2.2. Glutathione S-transferase (GST) pull-down assays
293T cells were transiently transfected with 6Myc-tagged EWS-
ER81, EWS-NTD or ER81-CTD. After 36 h, the cells were harvested
in 600 Wl of 40 mM HEPES (pH 7.4), 10 mM EDTA, 150 mM NaCl
and pelleted for 3 min at 900Ug. The pellet was resuspended in 80 Wl
of 10 mM Tris, 30 mM Na4P2O7 (pH 7.1), 50 mM NaCl, 50 mM
NaF, 1% Triton X-100, 10 Wg/ml leupeptin, 2 Wg/ml aprotinin, 1 Wg/ml
pepstatin A, 1 mM phenylmethylsulfonyl £uoride (PMSF), 0.5 mM
Na3VO4, 2 mM DTT, and lysis was allowed to occur for 30 min on
ice. Then, debris was removed by centrifugation (10 min, 20 800Ug,
4‡C). Puri¢ed GST and GST-c-Jun were tumbled in 20 mM HEPES
(pH 7.4), 25 mM NaCl, 0.1% Tween-20, 10 Wg/ml leupeptin, 2 Wg/ml
aprotinin, 1 Wg/ml pepstatin A, 0.5 mM PMSF, 0.1 mM Na3VO4,
2 mM DTT with 25 Wl of glutathione agarose beads for 2 h at 4‡C,
and then again for 2 h after the addition of 10 Wl of 293T cell extract.
The beads were ¢nally washed four times in binding bu¡er and bound
proteins revealed by anti-Myc Western blotting.
2.3. Electrophoretic mobility shift assay
Bacterially expressed, puri¢ed GST-EWS-ER81 was incubated on
ice for 1 h in 10 mM Tris^HCl (pH 7.9), 5 mM MgCl2, 50 mM NaCl,
1 mM EDTA, 50 Wg/ml bovine serum albumin, 0.1% IGEPAL CA-
630, 0.1 Wg/Wl poly(dI-dC)*poly(dI-dC) with a 32P-labeled MMP-1
probe as described [9]. Where indicated, 0.5 Wl of an antibody directed
against the C-terminus of ER81 (anti-ETV-1 C20; Santa Cruz) was
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added. After incubation, samples were electrophoresed on a 5% poly-
acrylamide gel in 0.5UTBE at 4‡C. The gel was dried and exposed to
¢lm.
3. Results
3.1. EWS-ER81 and EWS-Fli-1 oncoproteins activate the
MMP-1 promoter
Five di¡erent ETS transcription factors can be fused to
EWS to generate oncogenic EWS-ETS fusion proteins [1].
One of these is EWS-ER81 (also called EWS-ETV-1) in which
the last 164 amino acids of ER81, including its ETS DNA
binding domain, are fused to the N-terminal 264 amino acids
of EWS [10]. When cotransfected with a luciferase reporter
gene driven by the human MMP-1 promoter containing se-
quences from 3525 to +15 [9] EWS-ER81 raised luciferase
activity by 4.7-fold over the vector control (Fig. 1A, top pan-
el), whereas neither ER81-CTD nor EWS-NTD alone had any
dramatic e¡ect on MMP-1 promoter activity. This was not
due to the fact that ER81-CTD and EWS-NTD were less
expressed than EWS-ER81 (Fig. 1A, bottom panel). To a
comparable level as observed with EWS-ER81 and similar
to recently reported transfection experiments with a di¡erent
MMP-1 (3517 to +63) reporter plasmid [11], another EWS-
ETS fusion protein, EWS-Fli-1, in which the ¢rst 264 EWS
amino acids are fused to the last 212 amino acids of Fli-1,
enhanced MMP-1 promoter activity (see Fig. 3A).
DNA binding sites for ETS proteins are characterized by a
5P-GGAA/T-3P core sequence [12], and two of these ETS sites
have been identi¢ed in the MMP-1 promoter at positions 388
to 385 and 348 to 345 (see Fig. 1C). Indeed, mutation of the
388/385 ETS site decreased MMP-1 promoter activity by
54% in the presence of EWS-ER81, whereas mutation of the
348/345 ETS site barely reduced the ability of EWS-ER81 to
activate the MMP-1 promoter (Fig. 1B). Similar results were
obtained with EWS-Fli-1 (data not shown). Altogether, EWS-
ETS fusion proteins activate the MMP-1 promoter in vitro
primarily through the 388/385 ETS site.
Furthermore, we obtained 30 EWS specimens with permis-
sion of the Mayo Institutional Review Board and stained
them with an anti-MMP-1 antibody as previously described
[13]. MMP-1 staining was observed in 3 out of 30 tumors
Fig. 1. A: 10 ng of Myc-tagged EWS-ER81, ER81-CTD, EWS-NTD or empty vector pCS3þ-6Myc were transfected into RK13 cells. Activa-
tion of the cotransfected MMP-1 luciferase reporter plasmid is depicted. The bottom panel shows a respective anti-Myc immunoprecipitation
followed by anti-Myc Western blotting. B: MMP-1 luciferase reporter, wild-type or mutated at the ETS sites 388/385 (GGAT to AAAT) and/
or 348/345 (GGAA to AAAA), was cotransfected with 10 ng of Myc-tagged EWS-ER81 or empty vector pCS3þ-6Myc into RK13 cells.
C: Partial sequence of the human MMP-1 promoter pointing out the juxtaposed AP-1 and ETS binding sites. D: Immunohistochemical detec-
tion of MMP-1 expression (brown color) in two representative EWSs.
Fig. 2. Binding of EWS-ER81 to a 32P-labelled MMP-1 promoter
fragment (394 to 362) was determined by electrophoretic mobility
shift assays. Where indicated, these assays were performed in the
presence of an anti-ER81 antibody or a 100-fold excess of non-la-
beled competitor oligonucleotides (MMP-1 or E74), wild-type or
mutated (pre¢x ‘m’) at the ETS core sequence (GGAT to AAAT).
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(Fig. 1D), indicating that MMP-1 is expressed in a subset of
EWSs in vivo.
3.2. EWS-ER81 binds to the MMP-1 promoter
Next, we tested DNA binding of EWS-ER81 to the MMP-1
promoter employing electrophoretic mobility shift assays with
a 32P-labeled oligonucleotide spanning MMP-1 promoter nu-
cleotides 397 to 362. EWS-ER81 was indeed capable of
binding this MMP-1 promoter fragment, and inclusion of
an anti-ER81 antibody resulted in supershift formation (Fig.
2). Further, this DNA binding was speci¢c since the non-ra-
diolabeled MMP-1 oligonucleotide suppressed the formation
of the EWS-ER81/32P-DNA complex, whereas a mutated
MMP-1 oligonucleotide did not. Similarly, an established
ER81 binding site, E74, but not a mutated E74 oligonucleo-
tide that is unable to associate with ER81 [14], competed with
the radiolabeled MMP-1 oligonucleotide for EWS-ER81 bind-
ing (Fig. 2). Together with our reporter gene studies, these
data show that EWS-ER81 can bind to the ETS site at 388
to 385 in order to activate the MMP-1 promoter in vitro.
However, and consistent with our transfection analysis, no
binding of EWS-ER81 to the ETS site at 348 to 345 of
the MMP-1 promoter was detectable (data not shown).
3.3. c-Jun collaborates with EWS-ER81 and EWS-Fli-1
The MMP-1 promoter contains an AP-1 binding site be-
tween nucleotides 373 to 367 which is in close proximity to
the ETS site at 388/385 (see Fig. 1C). Furthermore, AP-1 has
been shown to activate the MMP-1 promoter and play crucial
roles in tumorigenesis [15]. Thus, we analyzed whether EWS-
ER81 and EWS-Fli-1 may collaborate with AP-1 to stimulate
the MMP-1 promoter. Indeed, whereas either c-Jun, a major
component of AP-1, or EWS-ER81 alone activated MMP-1
transcription less than eight-fold, together c-Jun and EWS-
ER81 dramatically activated MMP-1 promoter activity by
32-fold; similar results were obtained for EWS-Fli-1 (Fig.
3A).
We wondered whether endogenous AP-1 is necessary for
EWS-ER81 to mediate MMP-1 promoter activation. Thus,
we mutated the AP-1 site within the MMP-1 promoter and
observed a reduction of promoter activity by more than 10-
fold (Fig. 3B), with EWS-ER81 being unable to stimulate this
mutated MMP-1 promoter. These data implicate that endog-
enous AP-1 critically contributes to the stimulation of MMP-1
transcription by EWS-ER81.
Next, we assessed the ability of c-Jun to activate MMP-1
gene transcription upon mutating both ETS sites at 388 to
385 and 348 to 345. As shown in Fig. 3C, c-Jun was able to
enhance EWS-ER81 dependent transcription of the mutated
Fig. 3. A: The MMP-1 luciferase reporter was cotransfected with 10 ng EWS-ER81 or 250 ng EWS-Fli-1 in the absence and presence of c-Jun
(600 ng). Due to di¡erent vector backbones, di¡erent amounts of EWS-ER81 and EWS-Fli-1 expression vector were utilized to obtain optimal
MMP-1 activation. B: E¡ects of mutating residues within the AP-1 binding site (370 to 368 from GTC to TGG; mAP1) in the MMP-1 pro-
moter on EWS-ER81-mediated transcription in RK13 cells. C: MMP-1 luciferase reporter, wild-type or mutated at the ETS sites 388/385 and
348/345, was cotransfected with 10 ng of Myc-tagged EWS-ER81 or empty vector pCS3þ-6Myc and 600 ng of c-Jun expression vector into
RK13 cells.
Fig. 4. A: Extracts from 293T cells transfected with Myc-tagged
EWS-ER81, ER81-CTD, EWS-NTD or empty vector pCS3þ-6Myc
were incubated with either GST or GST-c-Jun bound to glutathione
beads. Interacting proteins were detected by anti-Myc immunoblot-
ting. Asterisks indicate GST or GST-c-Jun that cross-reacted with
the anti-Myc antibody. B: A GAL4 DNA binding site-containing
luciferase reporter construct was cotransfected with 50 ng of either
the GAL4 DNA binding domain or GAL4-EWS-ER81 and VP16
or VP16-c-Jun into 293T cells. Resulting luciferase activities were
determined.
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MMP-1 promoter, albeit to a lesser degree relative to the
wild-type promoter. These data imply that EWS-ER81, even
when not bound to the above mentioned ETS sites of the
MMP-1 promoter, is able to collaborate with c-Jun.
One way of doing so would be through a physical interac-
tion between EWS-ER81 and c-Jun. To test for this, we em-
ployed a GST pull-down assay. Whereas EWS-ER81 was not
bound by the GST moiety itself, GST-c-Jun interacted with
EWS-ER81 (Fig. 4A). No interaction was detected with EWS-
NTD, but weak binding of ER81-CTD to GST-c-Jun was
noticeable. Thus, the EWS-ER81 fusion protein interacts
more strongly with c-Jun than its C-terminal portion.
To validate that EWS-ER81 and c-Jun also interact in vivo,
we performed a mammalian two-hybrid analysis. Here, EWS-
ER81 was fused to the DNA binding domain of the yeast
protein GAL4 and its transcriptional activity measured with
a GAL4 binding site-containing luciferase reporter (Fig. 4B).
The GAL4-EWS-ER81 fusion protein itself was transcription-
ally inactive in this assay. We then coexpressed c-Jun that was
N-terminally tagged with the very potent transactivation do-
main of the herpes simplex virus VP16 protein. VP16 and
VP16-c-Jun alone were incapable to strongly activate GAL4
binding site-driven transcription. However, when coexpressed
with GAL4-EWS-ER81, a robust transcriptional activation
was observed with VP16-c-Jun but not VP16 (Fig. 4B). These
results indicate that EWS-ER81 can interact with c-Jun in
vivo.
3.4. EWS-ER81, EWS-Fli-1 and p300
A variety of transcription factors were shown to interact
with the coactivator p300 to mediate RNA polymerase II-de-
pendent gene transcription [16]. Because both EWS and ER81
bind to p300 [17,18], we wished to address the question
whether p300 is also able to interact with the EWS oncopro-
tein EWS-ER81 and thereby facilitate EWS-ER81-mediated
transcription. Indeed, p300 was able to potentiate MMP-1
activation mediated by EWS-ER81 by two-fold (Fig. 5A).
Next, we assessed whether EWS-ER81-mediated transcription
was dependent on endogenous p300. To this end, we em-
ployed the adenoviral protein E1A that sequesters and there-
by functionally inactivates p300 [16]. E1A dramatically re-
duced MMP-1 promoter activity in the presence of EWS-
ER81, suggesting that endogenous p300 is required for
EWS-ER81 to e⁄ciently activate MMP-1 transcription. Con-
sistently, the repressive e¡ect of E1A could be alleviated by
overexpression of p300 (Fig. 5A), indicating that E1A indeed
acts to a great extent by sequestering p300. However, we were
unable to demonstrate any direct binding of p300 to EWS-
ER81 (data not shown).
How could then p300 be recruited to the MMP-1 pro-
moter? One way would be through AP-1 whose components,
c-Fos and c-Jun, have been shown to interact with p300 [16].
Consistent with such a view, E1A was even able to repress the
MMP-1 promoter in the absence of EWS-ER81 (Fig. 5A),
probably by preventing the collaboration between endogenous
Fig. 5. A: 10 ng of 6Myc-EWS-ER81 were expressed together with p300 (2.5 Wg) and E1A (20 ng) as indicated in RK13 cells. Activation of
the cotransfected MMP-1 luciferase reporter is presented. The bottom panel shows comparable expression of EWS-ER81 by anti-Myc Western
blotting. B: Similar, coexpression of 6Myc-EWS-ER81 (150 ng), p300 (250 ng) and c-Jun (250 ng) and their e¡ects on MMP-1 promoter activ-
ity. In order to detect maximal cooperation, di¡erent amounts of expression plasmids were utilized than before. C,D: Analogous to A and B
with EWS-Fli-1 instead of EWS-ER81.
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AP-1 and p300. To further explore this conjecture, we coex-
pressed c-Jun and p300 and observed that they indeed colla-
borated to induce MMP-1 transcription (Fig. 5B). Addition-
ally, p300 was able to enhance MMP-1 promoter stimulation
jointly mediated by c-Jun and EWS-ER81. Thus, EWS-ER81
collaborates with c-Jun and the c-Jun-associated cofactor,
p300, in order to upregulate the MMP-1 gene in vitro. As
shown in Fig. 5C,D, an equivalent conclusion can be drawn
for EWS-Fli-1.
4. Discussion
EWSs harbor tumor-speci¢c EWS-ETS proteins. These fu-
sion proteins are essential for initiating and maintaining the
tumor phenotype, yet only little is known about the mecha-
nisms of EWS-ETS action in the process of cell transforma-
tion [1]. In this report, we demonstrated that two EWS-ETS
oncoproteins, EWS-ER81 and EWS-Fli-1, collaborate with
the proto-oncoprotein c-Jun and the cofactor p300 in regulat-
ing gene transcription.
c-Jun is a critical regulator of cell proliferation and a proto-
oncoprotein [15]. Our data show that c-Jun functionally co-
operates with EWS-ER81 and EWS-Fli-1, and even physically
interacts with EWS-ER81. Interestingly, c-Jun may also be
upregulated in EWS [19]. As such, EWS-ER81, or EWS-Fli-
1, and c-Jun might be destined to collaborate in EWS. Even if
gene promoters have only a binding site for either EWS-ER81
or c-Jun, these two proteins may co-regulate transcription as
long as the protein binding to DNA is capable of recruiting
the other through protein^protein interactions. This might be
the reason why the MMP-1 promoter is still somewhat induc-
ible by EWS-ER81 even when the ETS sites at both 388/385
and 348/345 are mutated.
Immunohistochemical analysis revealed that MMP-1 is ex-
pressed in 10% of EWSs, indicating that MMP-1 might indeed
be upregulated by EWS-ETS oncoproteins in tumors. The
reason why 90% of EWSs display no MMP-1 upregulation
could be due to the fact that AP-1 components such as
c-Jun are not always upregulated or that the protein levels
of EWS-ETS oncoproteins di¡er, thereby not allowing an
e⁄cient activation of MMP-1 transcription in all EWSs.
In addition to MMP-1, several other MMPs are overex-
pressed in EWS, namely MMP-2, -3 and -9 [11,19,20] that
can be regulated by c-Jun [21,22]. Interestingly, the binding
site for c-Jun is also very close to an ETS site in the MMP-9
promoter, suggesting that closely spaced binding sites for
c-Jun and EWS-ETS oncoproteins may often be responsible
for the upregulation of an MMP gene in EWS. In conclusion,
collaboration between EWS-ETS oncoproteins and c-Jun may
be widespread and identi¢cation of further common target
genes might reveal important regulatory mechanisms associ-
ated with EWS.
The coactivator p300 promotes gene transcription by bridg-
ing between DNA binding transcription factors and the basal
transcription machinery, by providing a sca¡old for integrat-
ing transcription factors, and by modifying transcription fac-
tors and chromatin through acetylation [16]. Previous reports
have shown that both EWS and ER81 interact with p300
[17,18], but we have been unable to detect a physical interac-
tion between EWS-ER81 and p300. This could be due to the
fact that the EWS-ER81 fusion protein contains only the
NTD of EWS, which does not interact with p300 [17], and
the CTD of ER81, which lacks ER81 amino acids 249^313
that may be required for the interaction with p300 [18].
Nevertheless, our analysis shows that EWS-ER81 (as well as
EWS-Fli-1) and p300 functionally collaborate on the MMP-1
promoter in vitro. One potential mechanism for this collabo-
ration is that c-Jun co-recruits p300 and EWS-ER81 (or EWS-
Fli-1), thereby allowing for a functional collaboration between
EWS-ER81 (or EWS-Fli-1) and p300. The formation of such
a ternary complex consisting of EWS-ER81 (or EWS-Fli-1),
c-Jun and p300 may be instrumental for the dysregulation of
many genes and thereby provide one mechanism leading to
cell transformation and ultimately to the EWS phenotype.
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